About: Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2
Creator	Shen, Jun Xie, Yi Qin, Chen, Huai-Yong Du, Yan-Qing Miao, Shu-Yan Sun, Hai-Bai Wu, Jun-Pin Zhang, Li-Xia Zhong-Hua, ·
topic	covid:670a66815051b22fcc1eaae5aa1d444831c9e5af#this
Source	Medline; PMC
abstract	BACKGROUND AND OBJECTIVE: Without a specific antiviral treatment or vaccine, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, affecting over 200 countries worldwide. A better understanding of B- and T-cell immunity is critical to the diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19). METHODS: A cohort of 129 patients with COVID-19 and 20 suspected cases were enrolled in this study, and a lateral flow immunochromatographic assay (LFIA) and a magnetic chemiluminescence enzyme immunoassay (MCLIA) were evaluated for SARS-CoV-2 IgM/IgG detection. Additionally, 127 patients with COVID-19 were selected for the detection of IgM and IgG antibodies to SARS-CoV-2 to evaluate B-cell immunity, and peripheral blood lymphocyte subsets were quantified in 95 patients with COVID-19 to evaluate T-cell immunity. RESULTS: The sensitivity and specificity of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV infection were > 90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19. CONCLUSIONS: LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 infection, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1007/s40291-020-00486-3
bibo:pmid	32710269
has license	no-cc
sha1sum (hex)	670a66815051b22fcc1eaae5aa1d444831c9e5af
schema:url	https://doi.org/10.1007/s40291-020-00486-3
resource representing a document's title	Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2
has PubMed Central identifier	PMC7380500
has PubMed identifier	32710269
schema:publication	Mol Diagn Ther
resource representing a document's body	covid:670a66815051b22fcc1eaae5aa1d444831c9e5af#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/670a66815051b22fcc1eaae5aa1d444831c9e5af
is schema:about of	named entity 'detection' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'LATERAL' named entity 'IGG' named entity 'peripheral blood lymphocyte' named entity 'critical' named entity 'T-cell immunity' named entity 'IgM' named entity 'magnetic' named entity 'chemiluminescence' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'patients' named entity 'coronavirus disease 2019' named entity 'evaluate' named entity 'specific' named entity 'T-Cell' named entity 'IgG' named entity 'immunochromatographic' named entity 'lateral flow' named entity 'antiviral treatment' named entity 'assay' named entity 'T-cell immunity' named entity 'IgM' named entity 'IgM antibodies' named entity 'CD4' named entity 'spike protein' named entity 'IgM' named entity 'laboratory conditions' named entity 'IgG antibodies' named entity 'COVID' named entity 'antibody' named entity 'cellular immunity' named entity 'peripheral blood mononuclear cell' named entity 'effector cells' named entity 'COVID-19' named entity 'NRR' named entity 'antigenic determinants' named entity 'COVID' named entity 'COVID-19' named entity 'statistically significant' named entity 'antibody' named entity 'quality control' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'Flow cytometry' named entity '92.7' named entity '97.3' named entity 'flow cytometry' named entity 'IgM' named entity 'cellular immunity' named entity 'IgG antibodies' named entity 'Antibody-dependent enhancement' named entity 'diagnostic methods' named entity 'serological' named entity 'Beijing' named entity 'Peripheral blood lymphocyte' named entity 'IgG' named entity 'gold standard' named entity 'CD4 +' named entity 'COVID-19' named entity 'IgG' named entity 'chi-squared' named entity 'reverse transcription polymerase chain reaction' named entity 'antibodies' named entity 'IgG' named entity 'serum' named entity 'antiviral' named entity 'IgM' named entity 'venous blood'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software